Long-term Dexamethasone Treatment Increases Cardiac Galectin-3 Levels

Area of Science:

• Cardiology
• Endocrinology
• Molecular Biology

Background:

• Glucocorticoids are widely prescribed but can cause cardiac remodeling.
• Insulin resistance and hypertension are known side effects of glucocorticoids.
• Galectin-3 (gal-3) is implicated in cardiac remodeling and upregulated by insulin resistance.

Purpose of the Study:

• To investigate the effect of prolonged glucocorticoid administration on galectin-3 (gal-3) levels in rat myocardium.
• To determine if gal-3 is associated with cardiac hypertrophy induced by glucocorticoids.

Main Methods:

• Female Wistar Albino rats were divided into control and dexamethasone-treated groups.
• Dexamethasone was administered subcutaneously daily for 28 days at 1 mg/kg.
• Heart weight, body weight, and myocardial gal-3 expression (Western blot) were analyzed.

Main Results:

• Dexamethasone treatment significantly increased heart weight and heart-to-body weight ratios.
• A twofold increase in left ventricular galectin-3 expression was observed after 28 days of dexamethasone administration.
• These changes were statistically significant (p < 0.001).

Conclusions:

• This study is the first to demonstrate that dexamethasone administration elevates myocardial galectin-3 levels.
• The findings suggest a link between glucocorticoid use and increased gal-3 in the heart.
• This research may aid in developing therapeutics and emphasizes monitoring patients on long-term glucocorticoid therapy.